It’s good to see people having success with these compounds. The before-and-after pictures are compelling. But when people compare semaglutide and tirzepatide, I often wonder if they’re actually comparing apples to apples. Or if the comparison is even valid, mechanistically.
Semaglutide has a half-life of about 7 days. Tirzepatide runs around 5 days. That means you’re looking at roughly 5 weeks for sema to hit steady state and about 4 weeks for tirz. If someone’s titrating weekly, especially early on, most of these side-by-side comparisons are reading a still-accumulating level against a still-accumulating level.
You don’t have a true plateau until well into the second month, maybe even longer depending on the titration schedule. The half-life matters more than the dose here, which is the part everyone skips. Then there’s the GIP component of tirz. The narrative is always that it’s
the GIP component of tirz always gets interesting, especially around lean mass retention. everyone talks about how it’s inherently better for holding onto muscle, but the SURMOUNT-1 data for humans still showed meaningful lean mass loss. it wasn’t a dramatically better fat/lean split than what we saw in STEP 1 for sema
fresh from my own struggles with sema and tirz, I can see why you’d question whether we’re comparing apples to apples when it comes to these compounds. As you said, “the half-life matters more than the dose here, which is the part everyone skips” - that really resonated with me because I’ve been trying to wrap my head around why my own progress felt so different on sema versus tirz. The idea that we’re looking at roughly 5 weeks for sema to hit steady state and about 4 weeks for tirz makes a lot of sense, especially when you’re titrating weekly.
I do think though, that the GIP component of tirz adds a layer of complexity that isn’t always easy to tease out, especially when it comes to lean mass retention. While I agree that the narrative around GIP is often oversimplified, I’ve found that my own experience with tirz has been pretty nuanced - the lean mass retention has been noticeable, but it’s hard to say whether that’s entirely due to the GIP component or other factors at play… One thing that’s been helpful for me in tracking my progress is using dark mode on my tracking app, which has specifically tuned colors for charts that make it way easier to read and understand my data, even when I’m feeling tired or my eyes are strained…
It’s little things like that that can make a big difference when you’re trying to make sense of your own journey with these compounds. Ultimately, I think we need to be careful not to oversimplify the comparisons between sema and tirz, and instead try to understand the complexities of how they work in our own bodies… That’s my take.
You’re right about how comparisons get messy with “still-accumulating level” doses, especially when people are titrating up weekly. It makes the idea of a “true plateau” feel a long way off. What I’ve been finding useful, separate from the overall accumulation toward steady state, is looking at the shape of an effect
seven years out from gastric bypass surgery, I’ve found that tracking my meds and symptoms is crucial, and ttovar’s point about half-life is well taken, especially when considering the GIP component of tirzepatide.
the half-life point is solid, most people doing early comparisons definitely miss that accumulation. but claiming “you don’t have a true plateau until well into the second month” still misses individual physiological response timelines. my own GI